Almonertinib for Advanced NSCLC Patients With Rare Mutations in EGFR
NCT04785742
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
40
Enrollment
OTHER
Sponsor class
Conditions
Safety of Almonertinib
Interventions
DRUG:
Almonertinib
Sponsor
Sun Yat-sen University